Exercise on GLP-1 Drugs: What the Evidence Actually Shows
GLP-1 drugs produce major weight loss without supervised exercise, but roughly 25-39% of the weight lost is lean mass, versus 17.5% when lifestyle programs include resistance training. Exercise's clearest benefits show up in body composition and keeping weight off after the drug stops.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
No, you do not have to exercise for a GLP-1 drug to work. In the STEP 1 trial of semaglutide 2.4 mg, the drug produced large weight losses with nothing more than a calorie-restricted diet and encouragement to do activity such as walking [1]. Exercise does change other parts of the picture: it shifts how much of the weight you lose comes from lean tissue, it improves fitness and metabolic markers that the drug alone does not, and the strongest exercise signal in the research is about keeping weight off after the drug stops [9] [11].
What is settled is that the drugs work without supervised exercise, and that a meaningful share of the weight lost — 25% to 39% depending on the drug — is lean mass, compared with 17.5% in lifestyle programs that include resistance training [2]. What is not settled is whether that lean loss actually harms strength or physical function [3], and whether exercise programs can preserve muscle during incretin-based weight loss remains uncertain [7]. A sarcopenia-prevention review notes that GLP-1-specific evidence is limited, with many recommendations extrapolated from the general weight-loss, nutrition, exercise, and sarcopenia literature [8]. What happens with exercise at the moment the drug stops has not been directly evaluated in a randomized controlled trial [11].
Do the drugs work without exercise?
Yes. In STEP 1, 1,961 adults with overweight or obesity took semaglutide 2.4 mg weekly or placebo for 68 weeks. The semaglutide group lost an average of 14.9% of body weight versus 2.4% with placebo [1]. The lifestyle part of that trial was modest: a 500 kcal/day deficit diet, 150 minutes per week of activity such as walking encouraged, and counseling every 4 weeks. There was no supervised exercise program [1].
Tirzepatide trials showed even larger losses: 19.5% at the 10 mg dose and 20.9% at 15 mg, versus 3.1% for placebo [11]. Both the Wegovy and Zepbound labels state the drugs are indicated in combination with a reduced-calorie diet and increased physical activity [16] [17].
How much of the weight lost is lean mass?
A meta-analysis of 20 randomized trials with 15,782 participants, all measuring body composition with DXA or MRI, found that lean mass made up a substantial share of total weight lost on every incretin drug studied [2]:
| Approach | Lean mass as share of weight lost |
|---|---|
| Semaglutide | 35.2% (95% CI 31.5-38.9) |
| Tirzepatide | 25.4% (95% CI 22.8-28.0) |
| Liraglutide | 26.8% (95% CI 23.1-30.5) |
| Lifestyle intervention alone | 26.2% (95% CI 24.1-28.3) |
| Lifestyle plus resistance training | 17.5% (95% CI 14.2-20.8) |
The difference between incretins and lifestyle alone was not statistically significant (p=0.42), while lifestyle plus resistance training had the most favorable profile at 17.5% [2]. A separate BMJ network meta-analysis of 262 trials and 99,791 participants found tirzepatide produced both the largest fat-mass reduction (25.7%) and the largest lean-mass reduction (8.3%) among the drugs compared [4].
In the STEP 1 DXA subgroup of 140 participants, total lean mass fell in absolute kilograms, but lean mass as a proportion of body weight actually rose with semaglutide [1].
Is lean mass the same as muscle?
Not exactly, and the distinction matters for how worried to be. Lean mass includes organs, connective tissue, and bone in addition to contractile muscle, so lean-mass losses during treatment likely overstate the true loss of skeletal muscle [11].
A meta-analysis in the journal Drugs covered 60 studies and more than 1.2 million individuals. It found GLP-1 receptor agonists were associated with a decrease in lean or fat-free mass (SMD 0.52, k=28), but the certainty of evidence was low, and the changes appeared largely related to weight loss itself [3]. That analysis found no significant effect on bone mineral density, fractures, or WOMAC joint pain, function, or stiffness [3].
Whether lean-mass changes translate into impaired strength or physical performance remains uncertain, and the authors called for studies that directly measure strength and performance [3]. A sarcopenia-prevention review makes the same point from the clinical side: the central concern is not fat-free mass numbers on a scan, but whether changes come with reduced strength, impaired physical performance, frailty, or loss of independence [8].
What evidence exists for lifting weights while on a GLP-1?
Less than the headlines suggest. The widely quoted 17.5% figure comes from lifestyle-plus-resistance-training trials in general weight loss — not from trials of resistance training added to semaglutide or tirzepatide [2].
The closest real-world data is an Omada Health study of 245 adults (151 in the program, 94 controls) who had started a GLP-1 within the previous 8 weeks. Over 12 weeks, the virtual program group lost 6.0% of body weight versus 3.3% for controls, dropped body fat percentage by 3.3 points versus 1.6, and gained muscle mass percentage by 0.6 versus 0.2 [6]. Body composition was measured on home bioimpedance scales. This was a quasi-experimental study, not a randomized one, and every author was a full-time Omada employee, so it cannot prove the program caused the differences [6].
A review of sarcopenia prevention during GLP-1 therapy is blunt about the state of the field: current evidence is limited, and many recommendations are extrapolated from the general weight-loss, nutrition, exercise, and sarcopenia literature rather than from GLP-1-specific trials [8].
What did the tirzepatide-plus-testosterone case series find?
A retrospective case series followed 93 men with obesity and testosterone deficiency (morning total testosterone under 400 ng/dL) at a single clinic. All received weekly tirzepatide, testosterone cypionate injections, and coaching focused on resistance exercise and protein intake [7].
Over 12 months, weight fell 20.9 to 22.6 kg (18-20%), fat mass fell 16.6 to 17.1 kg, and lean body mass fell 4.0 to 6.1 kg. Bioimpedance-derived skeletal muscle mass rose 1.6 to 3.7 kg (4-12%), and grip strength rose 5.7 to 7.1 kg (18-21%) [7].
The authors themselves flag the limits: the uncontrolled multimodal design precludes attributing the results to any single component [7]. Three things were changed at once, total lean body mass still fell even as the bioimpedance muscle estimate rose, and this was a group of testosterone-deficient men at one clinic — so the series cannot be read as evidence that exercise preserves muscle on tirzepatide [7].
What did the S-LITE trial show about exercise plus a GLP-1?
S-LITE enrolled 195 adults with obesity (BMI 32-43, no diabetes). After an 8-week 800 kcal/day diet that produced a mean 13.1 kg loss, participants were randomized for one year to placebo, exercise, liraglutide 3.0 mg, or both [9].
The exercise program targeted the WHO minimum of 150 minutes of moderate or 75 minutes of vigorous activity per week, built around two supervised sessions (30 minutes of interval cycling plus 15 minutes of circuit training) and two individual sessions weekly, run by instructors with exercise physiology degrees [9].
| Strategy vs placebo at 1 year | Weight change |
|---|---|
| Exercise | -4.1 kg |
| Liraglutide | -6.8 kg |
| Exercise plus liraglutide | -9.5 kg |
The combination beat exercise alone by 5.4 kg, but it did not beat liraglutide alone by a significant margin — the difference was -2.7 kg with p=0.13 [9]. Where the combination clearly won was body composition and metabolism: body-fat percentage fell 3.9 points, roughly twice the drop seen with exercise (-1.7) or liraglutide (-1.9) alone, and only the combination improved HbA1c, insulin sensitivity, and cardiorespiratory fitness [9].
A bone analysis of the same trial found liraglutide alone reduced hip and spine bone mineral density compared with exercise and placebo, while the combination preserved bone density despite producing the largest weight loss [11].
What happens when you stop the drug, and does exercise change it?
Regain is the rule, not the exception. In the STEP 1 extension, participants who stopped semaglutide regained about two-thirds of their lost weight over the following year, and the share maintaining at least a 5% loss fell from 86.4% to 48.2%. The authors noted that the structured lifestyle support was withdrawn at the same time as the drug, which may have contributed [11].
In a post hoc analysis of SURMOUNT-4, 82.5% of people who stopped tirzepatide regained at least 25% of their lost weight by 52 weeks [11]. Across 18 randomized trials totaling about 3,771 participants, mean regain after stopping was 5.6 kg [11].
Controlled trial data show that exercise started during incretin treatment was linked to significantly less regain, greater sustained loss, and maintained activity levels one year after both the drug and the supervised program ended [11]. That evidence comes from a single liraglutide trial, so it may not generalize to semaglutide or tirzepatide [11]. No randomized controlled trial has directly evaluated exercise at the point of stopping, and the weight that comes back is disproportionately fat, with little recovery of lean mass [11].
How much exercise, and what kind, does the guidance point to?
The CDC, reflecting the Physical Activity Guidelines for Americans, sets the baseline: 150 minutes of moderate-intensity activity per week (or 75 minutes vigorous, or an equivalent mix), which can be split into 30 minutes a day, 5 days a week, plus muscle-strengthening on 2 or more days a week covering the legs, hips, back, abdomen, chest, shoulders, and arms [12].
The sarcopenia-prevention review lays out a stepwise framework: first build habitual movement up toward the aerobic targets, then add progressive resistance training 2-3 times per week with progressive overload, then sustain both long term with ongoing monitoring of strength, fat-free mass, and nutrition [8].
The discontinuation review reaches a similar conclusion from the other direction: combined aerobic plus resistance training is a plausible, low-risk adjunct during treatment, and resistance training, adequate dietary protein, and individualized screening are likely important pieces pending direct trials [11].
Who is at higher risk of muscle loss?
The sarcopenia review identifies the groups at greatest risk: older adults, frail individuals, people with low baseline muscle mass or strength, sarcopenic obesity, chronic kidney disease, cancer, chronic inflammatory disease, prolonged immobilization, low habitual activity, and rapid or marked weight loss [8].
For these patients, the review recommends baseline body composition and muscle function assessment, individualized resistance and multicomponent exercise, adequate protein, and periodic monitoring of composition, strength, and physical performance [8]. The review also notes that treatment pace and dose escalation may be individualized in higher-risk patients if fat-free mass or function worsens — a decision for the treating clinician [8].
Physical therapists have also entered this space. A perspective in a physical therapy journal notes that 1 in 8 US adults report having taken a GLP-1, and describes the PT role in mobility, pain relief, injury prevention, and mitigating lean-mass loss [14].
Does exercise speed weight loss, or does the drug improve fitness?
On raw weight loss, the clearest trial answer is no. In S-LITE, the exercise-plus-liraglutide arm did not lose significantly more weight than liraglutide alone at one year; the combination’s advantage showed up in body-fat percentage, fitness, and metabolic markers instead [9].
On fitness, the drug does not appear to be a booster. A sports-medicine review found preclinical evidence of endurance and mitochondrial effects, but clinical trials show no consistent improvement in human physical performance, and incretin therapies are not on the WADA Prohibited List [15].
Quality-of-life findings are similarly modest. STEP 1 reported improvements in SF-36 physical functioning (+1.80 points) and IWQOL-Lite-CT physical function (+9.43 points) versus placebo [1], while the BMJ network meta-analysis found no obesity drug improved quality of life beyond the minimally important difference, with all mean differences under 5 points against a threshold of 10 [4].
What safety points matter for training on these drugs?
The labels flag several issues relevant to anyone working out. Both Wegovy and Zepbound carry postmarketing reports of acute kidney injury, some requiring hemodialysis, mostly after gastrointestinal reactions that caused dehydration; both labels advise monitoring renal function in patients with reactions that could lead to volume depletion [16] [17]. In Wegovy’s weight-loss trials, acute kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years, some linked to GI reactions or dehydration [16]. Both labels also tell patients to drink fluids to reduce the chance of dehydration from nausea, vomiting, or diarrhea [16] [17].
Blood sugar is the second flag. Both labels warn that combining the drug with insulin or an insulin secretagogue can raise hypoglycemia risk, and that reducing the dose of those medications may be necessary — a prescriber decision, not something to adjust on your own [16] [17].
Finally, fatigue and dizziness are listed among the most common adverse reactions (at least 5% of patients) for Wegovy, and fatigue is listed for Zepbound; Zepbound’s hypotension rate was 1.6% versus 0.1% for placebo, occurring in association with GI events and dehydration [16] [17]. The BMJ network meta-analysis also found fatigue risk increased with several obesity drugs [4]. These are worth knowing on heavy training days.
What should you track besides the scale?
The case series measured grip strength by dynamometry and bioimpedance body composition at 3, 6, and 12 months [7]. The sarcopenia review’s monitoring list is broader: body composition trajectory, muscle strength, physical performance (grip strength, chair-rise, gait speed), protein adequacy, activity adherence, and any signs of functional decline [8].
On measurement tools, DXA is what the trials use as the standard, while home bioimpedance scales were the tool in the Omada study [2] [6].
What is settled and what is not?
Settled: the drug works without supervised exercise [1]; lean mass makes up roughly 25-39% of weight lost on incretins versus 17.5% with lifestyle plus resistance training [2]. From one liraglutide trial (S-LITE), exercise alongside a GLP-1 improved body-fat percentage, fitness, and metabolic markers even when it did not add much extra weight loss [9].
Unsettled: GLP-1-specific evidence on exercise remains limited, with many recommendations extrapolated from the general literature [8]; whether exercise programs can preserve muscle during incretin-based weight loss remains uncertain [7]; no randomized trial has directly evaluated exercise at the moment of discontinuation [11]; and the functional significance of lean-mass loss — whether it actually costs strength or independence — remains uncertain [3].
The strongest exercise signal in the research is post-treatment maintenance, and it comes from one liraglutide trial [11]. Until direct trials on semaglutide and tirzepatide exist, the honest summary is that combined aerobic and resistance training is a biologically plausible, low-risk adjunct to these drugs [11], with the clearest signals in body composition, fitness, and keeping weight off rather than in making the number on the scale fall faster.
Sources
- New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Diabetes, Obesity and Metabolism. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2026.
- Drugs. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. September 12, 2026.
- BMJ. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. July 8, 2026.
- BMJ Open. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. April 22, 2026.
- Diabetes, Obesity and Metabolism. Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss.
- Obesity Pillars. Increasing skeletal muscle mass and strength during incretin-based weight loss. September 2026.
- Journal of Clinical Medicine. Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy.
- New England Journal of Medicine. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
- eClinicalMedicine. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. 2024.
- Healthcare. Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance.
- Centers for Disease Control and Prevention. Adult Activity: An Overview.
- American Journal of Clinical Nutrition. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. 2025.
- PubMed. Transforming Care: Implications of Glucagon Like Peptide-1 Receptor Agonists on Physical Therapist Practice.
- International Journal of Molecular Sciences. Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications—A Narrative Review.
- DailyMed. WEGOVY- semaglutide injection, solution; WEGOVY- semaglutide tablet.
- DailyMed. ZEPBOUND- tirzepatide injection, solution; ZEPBOUND KWIKPEN- tirzepatide injection, solution.
Frequently asked questions
Does exercise make Ozempic or Wegovy work faster?
The best head-to-head evidence comes from the S-LITE trial, which studied liraglutide, not Ozempic or Wegovy. There, exercise plus the drug did not produce significantly more weight loss than the drug alone at one year (-2.7 kg difference, p=0.13). The combination's edge was in body-fat percentage, fitness, and metabolic markers.
Cardio or weights while on a GLP-1?
The guidance points to both. The CDC baseline is 150 minutes of moderate aerobic activity weekly plus muscle-strengthening on 2 or more days. A discontinuation review describes combined aerobic plus resistance training as a biologically plausible, low-risk adjunct to incretin therapy, and a sarcopenia-prevention review frames it as building aerobic activity first, then adding progressive resistance training.
How many days a week should I strength train?
The CDC recommends muscle-strengthening on 2 or more days a week covering all major muscle groups. A sarcopenia-prevention review for GLP-1 patients frames it as progressive resistance training 2-3 times per week with progressive overload.
Will I lose muscle on Zepbound if I never lift?
Lean mass made up 25.4% of total weight lost on tirzepatide in a meta-analysis of 15,782 participants. Whether that translates into lost strength or function is uncertain — the trials mostly measured tissue mass, not performance, and studies of strength are still needed.
Is it safe to work out when nauseated during dose increases?
The labels warn that nausea, vomiting, and diarrhea can cause dehydration, which can lead to acute kidney injury, some cases requiring hemodialysis. Both labels advise drinking fluids and reporting symptoms that do not go away.
Why does my energy drop after a dose increase?
Fatigue is listed among the most common adverse reactions (at least 5% of patients) for both Wegovy and Zepbound, and dizziness is listed for Wegovy. A network meta-analysis of 262 trials also found fatigue risk increased with several obesity drugs.
Should I keep exercising after stopping the drug?
That is where the evidence is strongest. People who started exercise during incretin treatment showed less regain and more sustained loss one year after the drug ended, though this comes from a single liraglutide trial and no trial has directly evaluated exercise at discontinuation.
Do GLP-1s improve athletic performance or count as doping?
A sports-medicine review found preclinical endurance and mitochondrial effects, but clinical trials show no consistent improvement in human physical performance. Incretin therapies are not on the WADA Prohibited List.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.